Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eusol Biotech Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, which indicates a highly concentrated prosecution environment. By working with only 1 distinct examiner, the company can focus its legal strategy on a single set of procedural expectations and examination preferences.
The prosecution is further localized within 1 distinct art unit, suggesting that the company's innovations are situated in a specific technical niche. FISCHER, JOSEPH is identified as the busiest examiner for this portfolio and is currently handling 1 busiest examiner pending office action. This examiner is responsible for the entirety of the company's active office actions at the patent office.
For a practitioner, the presence of 1 busiest examiner pending action under FISCHER, JOSEPH means that the timeline for the portfolio is entirely dependent on this individual's review. The focus remains on the 1 pending office action and the specific standards of the 1 distinct art unit. This structure allows for a targeted approach without the complexity of coordinating across different patent office divisions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18675786 | STABILIZED AFGF COMPOSITIONS | FISCHER, JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18675786 | STABILIZED AFGF COMPOSITIONS | FISCHER, JOSEPH | 1658 | §103DP | Non-Final OA | — | Pending | May 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEusol Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph Fischer has the most, with 1 of Eusol Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
